Ástralía - enska - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - oseltamivir phosphate -

Kanada - enska - Health Canada

novo nordisk canada inc - insulin isophane human biosynthetic - suspension - 100unit - insulin isophane human biosynthetic 100unit - insulins

Kanada - enska - Health Canada

novo nordisk canada inc - insulin injection human biosynthetic; insulin isophane human biosynthetic - suspension - 30unit; 70unit - insulin injection human biosynthetic 30unit; insulin isophane human biosynthetic 70unit - insulins

Kanada - enska - Health Canada

novo nordisk canada inc - insulin injection human biosynthetic - solution - 100unit - insulin injection human biosynthetic 100unit - insulins

Ísrael - enska - Ministry of Health

novartis israel ltd - rituximab - concentrate for solution for infusion - rituximab 10 mg / 1 ml - rituximab - rixathon is indicated for the following indications: * non-hodgkin’s lymphoma (nhl): rixathon is indicated for the treatment of patients with relapsed or refractory low-grade or follicular, b-cell non-hodgkin’s lymphoma. rixathon is indicated for the treatment of previously untreated patients with low-grade or follicular lymphoma in combination with chemotherapy.rixathon is indicated for the treatment of patients with cd20 positive diffuse large b-cell non-hodgkin's lymphoma in combination with chop chemotherapy. rixathon maintenance therapy is indicated for the treatment of follicular lymphoma patients responding to induction therapy. * chronic lymphocytic leukaemia (cll): rixathon in combination with chemotherapy is indicated for the treatment of patients with previously untreated and relapsed/refractory chronic lymphocytic leukaemia. only limited data are available on efficacy and safety for patients previously treated with monoclonal antibodies including rixathon or patients refractory to previous rixathon plus chemotherapy.* granulomatosis with polyangiitis and microscopic polyangiitis: rixathon, in combination with glucocorticoids, is indicated for the treatment of adult patients with granulomatosis with polyangiitis (gpa) (wegener’s granulomatosis (wg) and microscopic polyangiitis (mpa).*pemphigus vulgaris (pv):rixathon is indicated for the treatment of adult patients with moderate to severe pemphigus vulgaris (pv)

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - oseltamivir phosphate, quantity: 59.1 mg (equivalent: oseltamivir, qty mg) - capsule, hard - excipient ingredients: titanium dioxide; croscarmellose sodium; povidone; sodium stearylfumarate; gelatin; pregelatinised maize starch; iron oxide black; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - talminex is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,talminex is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - oseltamivir phosphate, quantity: 39.4 mg (equivalent: oseltamivir, qty mg) - capsule, hard - excipient ingredients: gelatin; pregelatinised maize starch; titanium dioxide; iron oxide red; povidone; sodium stearylfumarate; iron oxide yellow; croscarmellose sodium; purified talc; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - talminex is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,talminex is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

accelagen pty ltd - oseltamivir phosphate, quantity: 98.5 mg (equivalent: oseltamivir, qty mg) - capsule, hard - excipient ingredients: iron oxide red; croscarmellose sodium; purified talc; iron oxide black; gelatin; titanium dioxide; pregelatinised maize starch; iron oxide yellow; sodium stearylfumarate; povidone; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; potassium hydroxide - talminex is indicated for the treatment of infections due to influenza a and b viruses in adults and children including full-term neonates. treatment should commence as soon as possible, but no later than 48 hours after the onset of the initial symptoms of infection.,talminex is indicated for the prevention of influenza in adults and children aged 1 year and older. vaccination is the preferred method of routine prophylaxis against infection with influenza virus.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

silver health - silver, quantity: 0.03 mg/ml - solution - excipient ingredients: - helps decrease/reduce/relieve symptoms of mild allergies ; decrease/reduce/relieve itchy/prickling skin associated with mild eczema/dermatitis ; decrease/reduce/relieve symptoms of mild psoriasis ; decrease/reduce/relieve symptoms of mild, superficial skin fungal infections ; soothes/relieves heat rash ; decrease/reduce/relieve symptoms of medically diagnosed shingles ; helps healing of mild skin burn/sunburns ; enhance/improve healing of minor skin wound/cuts/scratches/abrasions ; decrease/reduce/relieve symptoms of insect bite/sting

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - adalimumab, quantity: 40 mg - injection, solution - excipient ingredients: mannitol; monobasic sodium phosphate dihydrate; water for injections; sodium chloride; sodium hydroxide; citric acid monohydrate; sodium citrate dihydrate; dibasic sodium phosphate dihydrate; polysorbate 80 - rheumatoid arthritis idacio is indicated for reducing signs and symptoms, as well as inhibiting the progression of structural damage in adult patients with moderate to severely active rheumatoid arthritis. this includes the treatment of patients with recently diagnosed moderate to severely active disease who have not received methotrexate.,idacio can be used alone or in combination with methotrexate.,juvenile idiopathic arthritis polyarticular juvenile idiopathic arthritis idacio in combination with methotrexate is indicated for reducing the signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older who have had an inadequate response to one or more disease modifying anti-rheumatic drugs (dmards). idacio can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.,enthesitis-related arthritis idacio is indicated for the treatment of enthesitis-related arthritis in children, who have had an inadequate response to, or who are intolerant to, conventional therapy.,psoriatic arthritis idacio is indicated for the treatment of signs and symptoms, as well as inhibiting the progression of structural damage, of moderate to severely active psoriatic arthritis in adult patients where response to previous dmards has been inadequate.,ankylosing spondylitis idacio is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis.,crohn?s disease in adults and children (? 6 years) idacio is indicated for the treatment of moderate to severe crohn?s disease, to reduce the signs and symptoms of the disease and to induce and maintain clinical remission in patients;,? who have had an inadequate response to conventional therapies or, ? who have lost response to or are intolerant to infliximab,ulcerative colitis idacio is indicated for the treatment of moderate to severe ulcerative colitis in adult patients who have had an inadequate response to conventional therapy or who are intolerant to or have medical contraindications for such therapies. patients should show a clinical response within 8 weeks of treatment to continue treatment beyond that time. (see 5.1 pharmacodynamic properties-clinical trials).,psoriasis in adults and children idacio is indicated for the treatment of moderate to severe chronic plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy.,idacio is indicated for the treatment of severe chronic plaque psoriasis in children and adolescent patients from 4 years of age who have had an inadequate response to or are inappropriate candidates for topical therapy and phototherapy.,hidradenitis suppurativa in adults and adolescents (from 12 years of age) idacio is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in patients with an inadequate response to conventional systemic hidradenitis suppurativa therapy.,uveitis idacio is indicated for the treatment of non-infectious intermediate, posterior and pan-uveitis in adult patients who have had an inadequate response to corticosteroids, in patients in need of corticosteroid sparing, or in whom corticosteroid treatment is inappropriate.